|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
|
|
gptkbp:acquiredBy
|
gptkb:Counsyl
Assurex Health
Sividon Diagnostics
|
|
gptkbp:CEO
|
gptkb:Paul_J._Diaz
Bryan Riggsbee
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:focus
|
neurology
oncology
women's health
personalized medicine
genetic testing
|
|
gptkbp:foundedIn
|
1991
|
|
gptkbp:founder
|
gptkb:Walter_Gilbert
gptkb:Mark_Skolnick
gptkb:Peter_Meldrum
Dennis W. Farrar
Kevin Kimberlin
|
|
gptkbp:headquartersLocation
|
gptkb:Salt_Lake_City,_Utah,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Myriad Genetics, Inc.
|
|
gptkbp:industry
|
gptkb:biotechnology
molecular diagnostics
|
|
gptkbp:keyPerson
|
gptkb:Paul_J._Diaz
Bryan Riggsbee
|
|
gptkbp:legalForm
|
gptkb:company
|
|
gptkbp:notableFor
|
Supreme Court case Association for Molecular Pathology v. Myriad Genetics, Inc.
patenting BRCA1 and BRCA2 genes
|
|
gptkbp:numberOfEmployees
|
approximately 2,700 (2023)
|
|
gptkbp:parentCompany
|
independent
|
|
gptkbp:product
|
BRACAnalysis
EndoPredict
GeneSight
Prolaris
Vectra DA
myRisk Hereditary Cancer
|
|
gptkbp:revenue
|
$690 million (2022)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:MYGN
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ:_MYGN
|
|
gptkbp:website
|
https://www.myriad.com/
|
|
gptkbp:bfsParent
|
gptkb:NASDAQ:_MYGN
gptkb:Association_for_Molecular_Pathology_et_al._v._Myriad_Genetics,_Inc.,_et_al.
gptkb:Association_for_Molecular_Pathology_v._Myriad_Genetics,_Inc.
|
|
gptkbp:bfsLayer
|
8
|